
Opinion|Videos|October 11, 2024
Older Adults, High-Risk Populations, and Severe Illness
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Key Takeaways
- Older adults, especially those with chronic heart or lung diseases, are at high risk for severe RSV illness.
- Severe RSV can result in hospitalization, long-term respiratory complications, and increased mortality in older adults.
Carrie Koenigsfeld, PharmD, FAPhA, discusses the CDC’s recommendation for an RSV vaccine for all adults aged 75 years and older, as well as those aged 60 to 74 years at increased risk, and outlines the conditions that elevate the risk for severe illness, including the implications of severe illness, such as hospitalization, long-term effects, complications, comorbidities, and mortality, while also comparing how RSV infection affects older vs younger adults.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- The CDC recommends an RSV vaccine for all adults aged 75 years and older and for adults aged 60 to 74 years who are at increased risk for severe RSV. What conditions put an individual at high risk for developing severe illness?
- Describe the implications of severe illness (ie, hospitalization, long-term effects, complications, comorbidities, mortality).
- How does RSV infection affect older vs younger adults?
Advertisement
Related to this article

BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.

A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.

Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.

American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.

fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.

Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.

A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
2
What the 2025-2030 Dietary Guidelines Mean for Heart Health
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
5

